abstract Learning Objectives: After completing this course, the reader will be able to:
Describe the oncogenic drivers in DLBCL, especially those that have recently been …

Diffuse large B-cell lymphoma (DLBCL) is classified into prognostically distinct germinal
center B-cell (GCB) and activated B-cell subtypes by gene expression profiling (GEP) …

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma worldwide and
consists of a heterogeneous group of cancers classified together on the basis of shared …

BACKGROUND. The development of gene expression profiling and tissue microarray
techniques have provided more information about the heterogeneity of diffuse large B‐cell …

Diffuse large B-cell lymphoma (DLBCL) displays striking heterogeneity at the clinical,
genetic, and molecular levels. Clinical prognostic models can define a population at high …

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
in the Western world, accounting for approximately 30,000 new cases per year in the United …

Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 30% to 40% of all non-
Hodgkin lymphoma (NHL) cases. Although the course of the disease is usually aggressive …

Diffuse large B-cell lymphoma (DLBCL) is a genomically heterogenous disease comprised
of many subtypes that display significantly different clinical outcomes, in the context of …

Diffuse large B‐cell lymphoma (DLBCL) is the most commonly occurring form of non‐
Hodgkin lymphoma in the western world. Until the mid 1990s the incidence of DLBCL …

Diffuse large B-cell lymphoma (DLBCL) is characterized by clinical and molecular
heterogeneity; however, this heterogeneity is rarely taken into account by standard-of-care …